ORIC Pharmaceuticals (NASDAQ: ORIC)
$8.72
(-5.1%)
-$0.47
Price as of April 22, 2024, 4:00 p.m. ET
ORIC Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
ORIC Pharmaceuticals Company Info
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
News & Analysis
Featured Article
Why Shares of Oric Pharmaceuticals Jumped Monday
Private investors agreed to spend $85 million to purchase the company's stock.
Jim Halley | Jun 26, 2023
Featured Article
Why ORIC Pharmaceuticals Stock Is Crashing Today
The company discontinued development of its lead clinical program.
Keith Speights | Mar 22, 2022
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.